Compare UP & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UP | AVXL |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | 1250 | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 294.4M | 289.1M |
| IPO Year | N/A | 2013 |
| Metric | UP | AVXL |
|---|---|---|
| Price | $6.52 | $3.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | ★ 1.6M | 871.6K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $2.61 |
| 52 Week High | $8.16 | $13.99 |
| Indicator | UP | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 79.16 | 47.40 |
| Support Level | $0.84 | $2.93 |
| Resistance Level | $8.16 | $3.76 |
| Average True Range (ATR) | 0.57 | 0.18 |
| MACD | 0.50 | 0.03 |
| Stochastic Oscillator | 77.26 | 23.81 |
Wheels Up Experience Inc is a provider of on-demand private aviation. The company offers a private aviation solution with a large and diverse aircraft fleet, delivered through a mix of charter solutions and its membership program that utilizes its controlled aircraft fleet and a network of safety-vetted charter operators. Through its partnership firm, it provides members and customers with an offering across private and premium commercial travel. It generates the majority of its revenue from member and customer flights through its membership program and charter solutions, as well as from membership fees and other activities and services, including group charter flights, cargo flights, and special missions. Geographically, the company generates maximum revenue from the United States.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.